Vitaeris
999 W Hastings Street
Vancouver
British Columbia
V6C 2W2
United States
Tel: 844-448-2580
Website: https://www.vitaerisbio.com/
About Vitaeris
Founded in early 2016, Vitaeris is a clinical-stage biopharmaceutical company based in Vancouver, British Columbia, Canada focused on the development of the anti-interleukin-6 (IL-6) monoclonal antibody clazakizumab. Clazakizumab is a best-in-class IL-6 antagonist that has been studied in clinical trials involving over one thousand patients worldwide.
Clazakizumab (formerly known as ALD518) was originally discovered and developed by Alder Biopharmaceuticals in cancer and rheumatologic conditions, and exclusively licensed on a worldwide basis to Vitaeris in May 2016. In December 2017, Vitaeris and CSL announced an exclusive strategic collaboration and purchase option agreement.
YEAR FOUNDED:
2016
LEADERSHIP:
Co-Founder, President & CEO: Kevin Chow, Ph.D.
CMO: Dr. Edward Chong, MBChB, MRCP, Dip Pharm Med
CFO: John Parkinson, CPA, CA, B.Comm, B.A.
Global Head, Strategic Development: Tim Waugh, BSc, DipM
3 articles about Vitaeris
-
CSL Behring, based in King of Prussia, Pennsylvania, is acquiring Vancouver, British Columbia-based Vitaeris. The two companies inked a strategic partnership in 2017 to accelerate the development of Vitaeris’s clazakizumab. At that time, CLS Behring also had an option to acquire Vitaeris, the the...
-
Vitaeris Announces Multiple Scientific Presentations Involving Clazakizumab at the 2019 American Transplant Congress
5/22/2019
Anti-Interleukin 6 Monoclonal Antibody for Antibody-Mediated Kidney Transplant Rejection
-
CSL and Vitaeris Announce Strategic Partnership with Option to Acquire
12/5/2017
CSL Limited and Vitaeris today announced that they have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab as a therapeutic option for solid organ transplant rejection.